GSK jumps as EMA starts bepirovirsen review; dividend payment due April 9
GSK shares rose after the European Medicines Agency accepted bepirovirsen for review as a potential first-in-class treatment for chronic hepatitis B. The move also comes a day before GSK’s cash dividend payment date of April 9, 2026, which can support near-term demand from income-focused investors.
1. What’s driving the stock today
GSK is trading higher after a key regulatory milestone in Europe: the European Medicines Agency accepted for review the marketing authorisation application for bepirovirsen in adults with chronic hepatitis B. Acceptance signals the application is sufficiently complete to start the EMA’s formal assessment process and refocuses attention on GSK’s pipeline beyond its current vaccines and specialty-medicines base. (gsk.com)
2. Why the bepirovirsen milestone matters
Bepirovirsen is positioned as a potential first-in-class therapy for chronic hepatitis B, a large global market with significant unmet need. A positive European outcome would expand GSK’s late-stage growth narrative and could meaningfully affect medium-term revenue expectations if launch timing and reimbursement line up favorably. (gsk.com)
3. Dividend timing adds a near-term tailwind
The move is also occurring just ahead of GSK’s scheduled dividend payment date on Thursday, April 9, 2026 for the previously declared quarterly dividend on the NYSE-listed ADR. While the stock’s February ex-dividend date has already passed, the proximity of the cash payment can still support demand from dividend-focused investors and systematic strategies. (marketbeat.com)